Roth MKM Reiterates Buy on BioRestorative Therapies, Maintains $15 Price Target
Portfolio Pulse from richadhand@benzinga.com
Roth MKM analyst Jonathan Aschoff has reiterated a 'Buy' rating on BioRestorative Therapies (NASDAQ:BRTX), maintaining a price target of $15.
August 14, 2023 | 1:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioRestorative Therapies (NASDAQ:BRTX) has been reiterated with a 'Buy' rating by Roth MKM analyst Jonathan Aschoff, with a maintained price target of $15.
The reiteration of a 'Buy' rating by a Roth MKM analyst indicates a positive outlook for BioRestorative Therapies. The maintained price target of $15 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100